Genzyme Wait for Higher Bid Risky Due to FDA Plant Deadline, Orbimed Says

Genzyme Corp.’s wait for a takeover offer higher than Sanofi-Aventis SA’s hostile bid is risky because of the biotechnology company’s manufacturing record, shareholder OrbiMed Advisors LLC said.
Bloomberg